

Submission of a mHealth initiative
to the Taskforce 'Data & Technology against Corona'

1. *Name of the application*

2. *Url of the application if available*

3. *Organisation (name, adress, url)*

4. *Contact person (name, mail, gsm)*

5. *General description*

6. *Key features*

7. Target user group(s)

8. What is the direct link to the Covid-19 crisis ?

9. Why is it urgent ?

10. Type of application
(advice, triage, monitoring,
teleconsult, ...)

11. Platforms
(web app, mobile app (iOS,
Android, ...))

12. Where are the data stored
(on device, on premise, in a cloud
environment) ?

13. Supported languages

14. Status of deployment

15. Cost for users

16. *GDPR compliance (see questions
in annex 1)*

17. *If platform for teleconsult,
compliance with Information
Security Committee guidelines
(see annex 2)*

18. *CE certification*

19. *Other information*

Annex 1

1. Does the application only process anonymous data, namely data which do not relate to an identified or identifiable natural person, or data rendered anonymous in such a manner that the data subject is not or no longer (re)identifiable, even when matching it with other (third party) data? If initially personal data are rendered anonymous, shortly describe the applied anonymization techniques
2. If the application does not only process anonymous data
 - a. For which purposes are personal data being used?
 - b. Which types of personal data are being used ? Are sensitive data (e.g. racial or ethnic, political, religious or philosophical beliefs, trade union, genetic data, biometric data for identification, health data, sexual) being used? Shortly motivate why these personal data are necessary for achieving the purposes
 - c. What is the applicable legal basis (e.g. contract, legitimate interest, consent, legal obligation, vital interest, public interest, health care provision by persons or organisations that have a care relationship with the data subject, ...) (see articles 6 and 9.2 GDPR) ?
 - d. Are you transparently informing users? If applicable according to the GDPR, does the user have the possibility to object?
 - e. Which IT security measures are in place (e.g. pseudonymised data, access control, ...)?
 - f. What is the maximum storage duration you envisage for the personal data?
3. Other risk impacting factors
 - g. Are there other risk increasing factors (e.g. data of children or minors, transfers to third parties (incl. subcontractors), transfers to other countries, ...)
 - h. If you consider a high risk for the rights & freedoms of citizens: did you perform a data protection impact assessment? In case of a residual high risk: did you contact the data protection authority?

Annex 2

1. Minimal conditions

- a. Consent of the patient
- b. Video communication via a tool with end-to-end encryption
- c. Video or audio communication is not stored on the platform used
- d. If, in addition to the possibility of video or audio communication, the tool provides other functions, they are offered in such a way as to enable users to comply with the rules of use below
- e. Documents containing personal data can only be exchanged through a system with end-to-end encryption and with a reliable system of authentication of the identity of the users; the two-factor authentication tools (possession and knowledge) integrated into the Federal Authentication Service (FAS), such as the electronic identity card, Itsme or, for patients, the authentication means generated within the Helena platform, are considered to be reliable systems of authentication of users' identities
- f. The patient is physically and mentally capable of working with a PC

2. Rules of use

- a. Video or audio communication is not stored by the participants in the communication
- b. Medicinal prescriptions are created electronically on Recip-e, and can be consulted by the patient via the Personal Health Viewer; the unique number of electronic prescription (the so-called RID), which does not contain any personal data, can be transferred to the patient
- c. In principle, documents that the care provider and / or the patient can consult via the eHealth Portal or the Personal Health Viewer are consulted there